{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:04:38Z","timestamp":1794895478374,"version":"4.9.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Measurable residual disease (MRD) assessment by flow cytometry (FC) plays an essential role in prognosis and therapy escalation of B-cell acute lymphoblastic leukemia (B-ALL). However, the high degree of expertise and manual analysis time required limits the availability of this assay. To overcome this limitation, we developed a data-enhancing artificial intelligence (AI) pipeline that accelerates and simplifies MRD analysis. Unaltered FC files from 171 B-ALL MRD-positive and 89 MRD-negative cases were processed through an AI pipeline trained with 31 expert-gated negative controls. Cluster-informed downsampling reduced FC files from 1.2 million to 155\u2009884 cells per case, on average, (87% cellularity reduction), whereas preserving small MRD populations (median, 100% retention for MRD of &amp;lt;1%) and allowing for true percentage MRD estimates using a correction factor. A deep neural network cell classifier automatically identified normal hematopoietic subsets (macro-averaged F1 score of 0.86); and an AI measure of anomaly discriminated B-ALL from benign mononuclear (area under the curve [AUC] of 0.98) or B-lymphoid cells (AUC of 0.94). Manual analysis of AI-enhanced files was completed in only 1.01 minutes per case, on average (standard deviation of \u00b10.57); with 100% positive agreement with conventional analysis (for MRD of \u22650.01%), 100% negative agreement, and excellent quantitative correlation (R2 = 0.92). Our cloud-based AI-enhancement solution accelerates B-ALL MRD identification without compromising test performance and has the potential of facilitating B-ALL MRD analysis by more clinical laboratories.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016126","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:10:57Z","timestamp":1758222657000},"page":"58-69","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry"],"prefix":"10.1182","volume":"10","author":[{"given":"Jansen N.","family":"Seheult","sequence":"first","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Otteson","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Timm","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Weybright","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4293","authenticated-orcid":false,"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-4485","authenticated-orcid":false,"given":"Horatiu","family":"Olteanu","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5701-0857","authenticated-orcid":false,"given":"Chuan","family":"Chen","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-2666","authenticated-orcid":false,"given":"April","family":"Chiu","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Horna","sequence":"additional","affiliation":[{"name":"1Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"7","key":"2026011308514129700_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/s41375-020-01100-5","article-title":"Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting","volume":"35","author":"Modvig","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2026011308514129700_bib2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.5858\/arpa.2022-0172-OA","article-title":"Association of minimal residual disease by a single-tube 8-color flow cytometric analysis with clinical outcome in adult B-cell acute lymphoblastic leukemia: a real-world study based on 486 patients","volume":"147","author":"Liao","year":"2023","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"2026011308514129700_bib3","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026011308514129700_bib4","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2026011308514129700_bib5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2006-08-041152","article-title":"End points to establish the efficacy of new agents in the treatment of acute leukemia","volume":"109","author":"Appelbaum","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2026011308514129700_bib6","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"issue":"26","key":"2026011308514129700_bib7","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2026011308514129700_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"2026011308514129700_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cyto.a.24670","article-title":"flowCut: an R package for automated removal of outlier events and flagging of files based on time versus fluorescence analysis","volume":"103","author":"Meskas","year":"2023","journal-title":"Cytometry A"},{"issue":"29","key":"2026011308514129700_bib10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21105\/joss.00861","article-title":"UMAP: uniform manifold approximation and projection","volume":"3","author":"McInnes","year":"2018","journal-title":"J Open Source Softw"},{"issue":"9","key":"2026011308514129700_bib11","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1093\/bioinformatics\/btaa042","article-title":"PARC: ultrafast and accurate clustering of phenotypic data of millions of single cells","volume":"36","author":"Stassen","year":"2020","journal-title":"Bioinformatics"},{"issue":"10","key":"2026011308514129700_bib12","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.3390\/cancers14102537","article-title":"Artificial intelligence enhances diagnostic flow cytometry workflow in the detection of minimal residual disease of chronic lymphocytic leukemia","volume":"14","author":"Salama","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026011308514129700_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2026011308514129700_bib14","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2026011308514129700_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cyto.b.21252","article-title":"Detection of minimal residual disease in B lymphoblastic leukemia using viSNE","volume":"88","author":"DiGiuseppe","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"2026011308514129700_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cyto.b.22084","article-title":"Machine learning optimized multiparameter radar plots for B-cell acute lymphoblastic leukemia minimal residual disease analysis","volume":"102","author":"Shopsowitz","year":"2022","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2026011308514129700_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.a.21148","article-title":"Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data","volume":"81","author":"Fi\u0161er","year":"2012","journal-title":"Cytometry A"},{"issue":"9","key":"2026011308514129700_bib18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cyto.a.23852","article-title":"Automated flow cytometric MRD assessment in childhood acute B- lymphoblastic leukemia using supervised machine learning","volume":"95","author":"Reiter","year":"2019","journal-title":"Cytometry A"},{"key":"2026011308514129700_bib19","doi-asserted-by":"crossref","first-page":"105314","DOI":"10.1016\/j.compbiomed.2022.105314","article-title":"Automated identification of cell populations in flow cytometry data with transformers","volume":"144","author":"W\u00f6dlinger","year":"2022","journal-title":"Comput Biol Med"},{"issue":"4","key":"2026011308514129700_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cyto.b.22143","article-title":"Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: a EuroFlow study","volume":"106","author":"Verbeek","year":"2024","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2026011308514129700_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ajcp\/aqaa242","article-title":"How I diagnose minimal\/measurable residual disease in B lymphoblastic leukemia\/lymphoma by flow cytometry","volume":"155","author":"Cherian","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2026011308514129700_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cll.2021.03.013","article-title":"Laboratory aspects of minimal \/ measurable residual disease testing in B-lymphoblastic leukemia","volume":"41","author":"Choi","year":"2021","journal-title":"Clin Lab Med"},{"issue":"5","key":"2026011308514129700_bib23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1309\/AJCPOOJRAVUN75GD","article-title":"B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model","volume":"143","author":"Shaver","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"2026011308514129700_bib24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2014.116707","article-title":"Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia","volume":"100","author":"Karawajew","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"2026011308514129700_bib25","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.3390\/cancers14215445","article-title":"Reliable flow-cytometric approach for minimal residual disease monitoring in patients with B-cell precursor acute lymphoblastic leukemia after CD19-targeted therapy","volume":"14","author":"Mikhailova","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026011308514129700_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cyto.b.21831","article-title":"A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia\/lymphoma can easily achieve the sensitivity of 2-in-10(6) and is superior to standard minimal residual disease assay: a study of 622 patients","volume":"98","author":"Tembhare","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"2026011308514129700_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.b.22120","article-title":"Highly sensitive single tube B-lymphoblastic leukemia\/lymphoma minimal\/measurable residual disease test robust to surface antigen directed therapy","volume":"104","author":"Gao","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2026011308514129700_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ejh.14102","article-title":"15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia\/lymphoma: real-world applicability and challenges","volume":"112","author":"Chatterjee","year":"2024","journal-title":"Eur J Haematol"},{"issue":"2","key":"2026011308514129700_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/leu.2012.234","article-title":"Flow cytometry and IG\/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL","volume":"27","author":"Garand","year":"2013","journal-title":"Leukemia"},{"issue":"20","key":"2026011308514129700_bib30","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011308514129700_bib32","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1182\/blood-2023-190275","article-title":"Machine learning enhancement of flow cytometry data accelerates the identification of minimal residual acute myeloid leukemia","volume":"142","author":"Seheult","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026011308514129700_bib33","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2024-199901","article-title":"Artificial intelligence-enhancement of flow cytometry data accelerates the identification of minimal residual chronic lymphocytic leukemia","volume":"144","author":"Chiu","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026011308514129700_bib34","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jid.2023.12.020","article-title":"Computational flow cytometry accurately identifies sezary cells based on simplified aberrancy and clonality features","volume":"144","author":"Seheult","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2026011308514129700_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/leu.2012.231","article-title":"Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"27","author":"Denys","year":"2013","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/58\/2478373\/blooda_adv-2025-016126-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/58\/2478373\/blooda_adv-2025-016126-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:51:51Z","timestamp":1768312311000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/58\/547303\/Artificial-intelligence-accelerates-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016126","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2025,12,30]]}}}